Advancing investigational treatment options for people living with cancer.
Solid Tumors - RTX-240
Rubius Therapeutics® is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. There are two Phase 1 arms enrolling adult patients with advanced solid tumor cancers – one to evaluate RTX-240 as monotherapy and the other to evaluate RTX-240 in combination with KEYTRUDA® (pembrolizumab)1.
Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, urothelial (bladder) cancer, head and neck cancer and triple-negative breast cancer, into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-224. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.